Publication | Closed Access

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

Dacomitinib Versus ErlotinibNon-small-cell Lung CancerMedicinePathologyImmune Checkpoint InhibitorArcher 1009Cancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology